Cellular Matrix for Donor Sites in Burn Patients

The data were presented at the annual meeting of the American Burn Association in Chicago (IL, USA).

The trial involved 82 patients and showed that the median healing time for donor site wounds treated with the cellular matrix, called OrCel, was one-third shorter than that of wounds treated with the current standard of care in the control group. In addition, treatment with OrCel resulted in significantly less scarring than standard care at 12 and 24 weeks after treatment. OrCel, the product of Ortec International, Inc. (New York, NY, USA), has been cleared by the US Food and Drug Administration (FDA).

OrCel is made of collagen sponge seeded with allogeneic epidermal and dermal cells. These cells secrete growth factors and cytokines normally found in acute human wounds and are believed to have a beneficial role in promoting tissue repair. Ortec believes its platform technology may extend to the regeneration of other human tissue such as tendons, ligaments, cartilage, bone, muscle, and blood vessels.




Related Links:
Ortec